Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody

US12258403B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Stephen Willingham · Stanford, US
• Maureen Howard · Los Altos Hills, US
• Jie Liu · Houston, US
• Ravindra Majeti · Palo Alto, US
• Susan Sweeney Prohaska · Mountain View, US
• Anne Kathrin Volkmer · Dressendorf, DE
• Jens-Peter Volkmer · Menlo Park, US
• Irving L. Weissman · Palo Alto, US

Key dates

• Filing date: Feb 3, 2023
• Grant date: Mar 25, 2025
• Expiry date: Feb 3, 2043

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.